Dupixent

Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData

Read more

Dupixent (dupilumab) gets DCGI approval to treat moderate-to-severe atopic dermatitis

Read more

Sanofi sees faster profit growth on Dupixent, flu vaccine

Read more

US FDA accepts Dupixent for priority review in adults with prurigo nodularis

Read more

Sanofi’s Dupixent wins US approval for bigger use

Read more

Sanofi and Regeneron get EU approval for Dupixent

Read more